Medigen Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 175.96 million compared to TWD 1,385.01 million a year ago. Net loss was TWD 116.2 million compared to net income of TWD 63.61 million a year ago. Basic loss per share from continuing operations was TWD 0.84 compared to basic earnings per share from continuing operations of TWD 0.46 a year ago. Basic loss per share was TWD 0.84 compared to basic earnings per share of TWD 0.46 a year ago.
For the nine months, sales was TWD 852.24 million compared to TWD 1,745.53 million a year ago. Net loss was TWD 320.67 million compared to TWD 129.74 million a year ago. Basic loss per share from continuing operations was TWD 2.31 compared to TWD 0.93 a year ago. Basic loss per share was TWD 2.31 compared to TWD 0.93 a year ago.